Differential expression of vascular endothelial growth factor165b in transitional cell carcinoma of the bladder
- PMID: 17628298
- DOI: 10.1016/j.urolonc.2007.01.015
Differential expression of vascular endothelial growth factor165b in transitional cell carcinoma of the bladder
Abstract
Angiogenesis or the development of new blood vessels from the surrounding vasculature is essential for the growth and progression of solid tumors. Vascular endothelial growth factor (VEGF), a positive regulator of angiogenesis, plays a pivotal role in tumor angiogenesis and shows a high expression in almost all known tumors, including transitional cell carcinoma (TCC) of the bladder. A novel isoform, VEGF(165)b containing a novel exon 9, was recently identified in renal cell carcinoma and was shown to be down-regulated and inhibitory in nature. We aimed to analyze quantitatively expression of this isoform, VEGF(165)b, in TCC of the bladder and compare it to the benign part of the same organ. A real-time reverse transcriptase polymerase chain reaction protocol was set up to quantitate simultaneously the messenger ribonucleic acid levels of VEGF and VEGF(165)b from 34 clinical samples representing bladder cancer and matched benign tissue. Expression of VEGF(165)b showed a >or=3.0-fold change in 27 of 34 (79%) bladder tumors than the benign samples. Increased expression of VEGF(165)b was seen in superficial tumors as compared to invasive tumors, which was statistically significant (P < 0.001). Therefore, VEGF(165)b was up-regulated in TCC of the bladder.
Similar articles
-
Alteration of the vascular endothelial growth factor and angiopoietins-1 and -2 pathways in transitional cell carcinomas of the urinary bladder associated with tumor progression.Anticancer Res. 2004 Sep-Oct;24(5A):2745-56. Anticancer Res. 2004. PMID: 15517881
-
Up-regulation of endothelial delta-like 4 expression correlates with vessel maturation in bladder cancer.Clin Cancer Res. 2006 Aug 15;12(16):4836-44. doi: 10.1158/1078-0432.CCR-06-0285. Clin Cancer Res. 2006. PMID: 16914569
-
Expression of vascular endothelial growth factor, receptor KDR and p53 protein in transitional cell carcinoma of the bladder.Urol Int. 2008;81(1):72-6. doi: 10.1159/000137644. Epub 2008 Jul 16. Urol Int. 2008. PMID: 18645275
-
Bladder cancer angiogenesis and metastasis--translation from murine model to clinical trial.Cancer Metastasis Rev. 2007 Dec;26(3-4):623-34. doi: 10.1007/s10555-007-9084-9. Cancer Metastasis Rev. 2007. PMID: 17726580 Review.
-
Bladder cancer.Curr Opin Oncol. 1996 May;8(3):259-63. Curr Opin Oncol. 1996. PMID: 8794154 Review.
Cited by
-
The route to personalized medicine in bladder cancer: where do we stand?Target Oncol. 2015 Sep;10(3):325-36. doi: 10.1007/s11523-015-0357-x. Epub 2015 Jan 30. Target Oncol. 2015. PMID: 25634607 Review.
-
Biomolecular predictors of urothelial cancer behavior and treatment outcomes.Curr Urol Rep. 2012 Apr;13(2):122-35. doi: 10.1007/s11934-012-0237-1. Curr Urol Rep. 2012. PMID: 22354565 Review.
-
Expression and clinical significance of hepaCAM and VEGF in urothelial carcinoma.World J Urol. 2010 Aug;28(4):473-8. doi: 10.1007/s00345-010-0573-z. Epub 2010 Jul 1. World J Urol. 2010. PMID: 20593288
-
Expression of livin and vascular endothelial growth factor in different clinical stages of human esophageal carcinoma.World J Gastroenterol. 2008 Oct 7;14(37):5749-54. doi: 10.3748/wjg.14.5749. World J Gastroenterol. 2008. PMID: 18837095 Free PMC article.
-
Do anti-angiogenic VEGF (VEGFxxxb) isoforms exist? A cautionary tale.PLoS One. 2012;7(5):e35231. doi: 10.1371/journal.pone.0035231. Epub 2012 May 2. PLoS One. 2012. PMID: 22567098 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical